Age-Related Changes in Pharmacokinetics — MCQs
Which of the following medications is a first-line antitubercular drug used routinely in children of all age groups without significant monitoring limitations?
Low apparent volume of distribution of drug indicates that:
Volume of distribution of a drug is 500 ml and target concentration of drug in blood is 5 g/L. 20% of administered drug is reached to systemic circulation. What will be the loading dose of that drug -
A 70 kg man was given a drug with a dose of 100 mg/kg body weight, twice daily. The half-life (t1/2) is 10 hours, the plasma concentration is 1.9 mg/mL, and the clearance is unknown. What is the clearance of this drug?
Which of the following drugs is known to have low first pass metabolism?
A drug is more likely to cause toxicity in elderly patients due to all of the following reasons except which of the following?
In which of the following conditions is digoxin most likely to accumulate to toxic levels?
2 year old child with length 85cm and weight of 11kg was found to have serum urea of 49mg/dl, serum creatinine 2mg/dl What is the estimated GFR of this child, as per Schwartz formula?
Which of the following is excreted in saliva?
Brand A of liposomal amphotericin B is of innovator company and brand B is of a generic company. AUC of Brand A is 124 mg.h/L and AUC of brand B is 115 mg.h/L. Which of the following statements is correct?
Age-Related Changes in Pharmacokinetics Indian Medical PG Practice Questions and MCQs
Question 1: Which of the following medications is a first-line antitubercular drug used routinely in children of all age groups without significant monitoring limitations?
- A. Ethambutol
- B. Streptomycin
- C. Pyrazinamide (Correct Answer)
- D. Combination of all first-line ATT agents
Explanation: ***Pyrazinamide*** - **Pyrazinamide** is one of the four core first-line antitubercular drugs (along with isoniazid, rifampicin, and ethambutol) [2, 4] and is used **routinely in children of all age groups** without significant monitoring limitations. - It is highly effective against **intracellular mycobacteria** in acidic environments, which are abundant in the early inflammatory stages of tuberculosis [1]. - Its inclusion is crucial for shortening the duration of treatment to 6 months and preventing the development of drug-resistant strains, especially in the initial intensive phase [3, 4]. *Ethambutol* - **Ethambutol** is indeed a first-line antitubercular drug, but its use in **children under 5 years** is often avoided or given with caution due to difficulty in monitoring for **optic neuritis** [1]. - Young children may not be able to reliably report visual changes (color vision defects, decreased visual acuity), making its safe administration challenging [1]. - WHO guidelines recommend avoiding ethambutol in children who cannot reliably report visual symptoms. *Streptomycin* - **Streptomycin** is an **aminoglycoside antibiotic** and is classified as a **second-line** (or alternative first-line) injectable antitubercular drug [3]. - It is primarily used for drug-resistant tuberculosis or in special circumstances where oral first-line regimens cannot be used. - It requires intramuscular injection and is associated with significant toxicities including **ototoxicity** (vestibular and auditory damage) and **nephrotoxicity**, making it unsuitable as a routine first-line option in children. *Combination of all first-line ATT agents* - While the standard treatment involves a **combination of four first-line drugs** (isoniazid, rifampicin, pyrazinamide, and ethambutol), this option describes a treatment regimen rather than answering which individual medication is a first-line drug [3]. - The question specifically asks for "which medication" (singular), making this option inappropriate as an answer.
Question 2: Low apparent volume of distribution of drug indicates that:
- A. Drug has low bioavailability
- B. Drug has low efficacy
- C. Drug is not extensively distributed to tissue (Correct Answer)
- D. Drug has low half life
Explanation: ***Drug is not extensively distributed to tissue*** - A **low apparent volume of distribution (Vd)** suggests that the drug primarily remains in the **vascular compartment**. - This indicates **minimal binding to peripheral tissues** and less distribution into extravascular spaces. *Drug has low bioavailability* - **Bioavailability** refers to the fraction of an administered drug that reaches the **systemic circulation unchanged**. - While related to drug disposition, a low Vd does not directly imply low bioavailability; a drug can have high bioavailability but remain largely in the blood. *Drug has low efficacy* - **Efficacy** is the maximum effect a drug can produce regardless of the dose. - Vd relates to drug distribution, not its pharmacological effect or **intrinsic activity** at its target. *Drug has low half life* - The **half-life** of a drug is determined by its **volume of distribution (Vd)** and **clearance (CL)** (t½ = 0.693 × Vd / CL). - While a low Vd can contribute to a shorter half-life if clearance is high, Vd alone does not solely determine half-life; clearance also plays a significant role.
Question 3: Volume of distribution of a drug is 500 ml and target concentration of drug in blood is 5 g/L. 20% of administered drug is reached to systemic circulation. What will be the loading dose of that drug -
- A. 1 gm
- B. 5 gm
- C. 25 gm
- D. 12.5 gm (Correct Answer)
Explanation: ***12.5 gm*** - The formula for loading dose (LD) is: LD = (Target Concentration × Volume of Distribution) / Bioavailability. - Given: Target Concentration = 5 g/L, Volume of Distribution = 500 mL = 0.5 L, Bioavailability = 20% = 0.2. - So, LD = (5 g/L × 0.5 L) / 0.2 = 2.5 g / 0.2 = **12.5 g**. *1 gm* - This value would be obtained if the target concentration was 2 g/L with 100% bioavailability, or if the calculation incorrectly handled the volume or bioavailability factor. - It does not account for the specified **bioavailability of 20%** or the given target concentration and volume of distribution. *5 gm* - This result would be obtained if the bioavailability was assumed to be 50% (LD = 2.5 g / 0.5 = 5 g), or if the volume of distribution was incorrectly used in the calculation. - This option does not correctly factor in the **20% bioavailability** of the administered drug. *25 gm* - This value would result from mistakes such as dividing by bioavailability of 10% instead of 20% (LD = 2.5 g / 0.1 = 25 g), or by multiplying bioavailability instead of dividing by it. - This answer significantly **overestimates** the required dose, which could lead to drug toxicity.
Question 4: A 70 kg man was given a drug with a dose of 100 mg/kg body weight, twice daily. The half-life (t1/2) is 10 hours, the plasma concentration is 1.9 mg/mL, and the clearance is unknown. What is the clearance of this drug?
- A. 20 liter/hr
- B. K is 0.0693
- C. 0.22 L/hr (Correct Answer)
- D. 0.02 L/hr
Explanation: ***0.22 L/hr*** - To calculate clearance at steady state, we use the formula: **Clearance (Cl) = Dose Rate / Css** (steady-state plasma concentration). - **Dose rate calculation**: 100 mg/kg × 70 kg × 2 doses/day = 14,000 mg/day = 583.33 mg/hr - **Converting plasma concentration**: 1.9 mg/mL = 1900 mg/L - **Clearance calculation**: Cl = 583.33 mg/hr ÷ 1900 mg/L = **0.307 L/hr** - **Note**: The calculated value (0.307 L/hr) does not exactly match any option. The marked answer (0.22 L/hr) is the closest approximation among the given choices. This discrepancy may arise from rounding in the original question parameters or implicit assumptions about bioavailability/volume of distribution. *0.02 L/hr* - This value is approximately 15 times lower than the calculated clearance. - Such low clearance would result in much higher plasma concentrations or require significantly lower dosing. *20 liter/hr* - This clearance is approximately 65 times higher than calculated, representing an unrealistically high value for this scenario. - Such high clearance would result in very low plasma concentrations unless extremely high doses were administered. *K is 0.0693* - This represents the **elimination rate constant (k)**, calculated as k = 0.693/t1/2 = 0.693/10 hr = 0.0693 hr⁻¹. - While mathematically correct for k, the question specifically asks for **clearance**, not the elimination rate constant. - Clearance is related to k by: Cl = k × Vd (volume of distribution).
Question 5: Which of the following drugs is known to have low first pass metabolism?
- A. Lidocaine
- B. Propranolol
- C. Theophylline (Correct Answer)
- D. Morphine
Explanation: ***Theophylline*** - **Theophylline** exhibits **low first-pass metabolism**, meaning a significant portion of the orally administered drug reaches systemic circulation unchanged. - This characteristic contributes to its relatively **high bioavailability** when given orally. *Lidocaine* - **Lidocaine** undergoes extensive **first-pass metabolism** in the liver, leading to very low oral bioavailability. - Due to this, it is typically administered **parenterally** (e.g., intravenously or topically) to achieve therapeutic concentrations. *Propranolol* - **Propranolol** is known for its significant **first-pass metabolism**, which results in a much lower bioavailability after oral administration compared to intravenous. - This extensive metabolism necessitates higher oral doses to achieve the same therapeutic effect as parenteral administration. *Morphine* - **Morphine** also undergoes substantial **first-pass metabolism** in the liver, where it is primarily glucuronidated. - This leads to a lower oral bioavailability compared to other routes of administration and contributes to a higher oral dose requirement.
Question 6: A drug is more likely to cause toxicity in elderly patients due to all of the following reasons except which of the following?
- A. decreased renal excretion of drugs
- B. decreased hepatic metabolism
- C. decreased volume of distribution (Correct Answer)
- D. increased receptor sensitivity
Explanation: ***decreased volume of distribution*** - A **decreased volume of distribution** would generally lead to a higher peak plasma concentration for a given dose, potentially increasing drug effect and thus toxicity, particularly for **hydrophilic drugs**. - However, for drugs that primarily distribute into **fat** or have a large volume of distribution, age-related changes in body composition (e.g., increased body fat, decreased total body water) can actually lead to an **increased volume of distribution** for some lipophilic drugs. *decreased renal excretion of drugs* - **Aging** is associated with a decline in **glomerular filtration rate (GFR)** and **renal tubular function**, leading to reduced drug clearance. - This results in a longer **half-life** and accumulation of renally excreted drugs, increasing the risk of **toxicity**. *decreased hepatic metabolism* - Liver size, blood flow, and the activity of some **cytochrome P450 enzymes** may decrease with age. - This leads to reduced **first-pass metabolism** and slower systemic clearance of many hepatically metabolized drugs, increasing their **bioavailability** and plasma concentrations. *increased receptor sensitivity* - Elderly patients often exhibit altered **pharmacodynamic responses**, including **increased sensitivity** to certain drugs. - This means a lower concentration of the drug at the receptor site can produce a greater therapeutic or toxic effect, making them more susceptible to **adverse drug reactions**.
Question 7: In which of the following conditions is digoxin most likely to accumulate to toxic levels?
- A. Renal insufficiency (Correct Answer)
- B. Chronic hepatitis
- C. Advanced cirrhosis
- D. Chronic pancreatitis
Explanation: ***Renal insufficiency*** - **Digoxin** is primarily excreted unchanged by the **kidneys**, so impaired renal function significantly prolongs its half-life and leads to drug accumulation. - Patients with kidney failure require **dose adjustments** or closer monitoring of **digoxin levels** to prevent toxicity. *Chronic hepatitis* - **Chronic hepatitis** primarily affects the **liver's metabolic capacity**, which is not the primary route of **digoxin elimination**. - While severe hepatic dysfunction can subtly impact drug disposition, it's not the main reason for **digoxin accumulation** like **renal insufficiency**. *Advanced cirrhosis* - **Advanced cirrhosis** involves severe liver dysfunction, which can alter drug metabolism and protein binding. - However, **digoxin's elimination** is mainly renal, so liver disease alone does not typically lead to significant accumulation unless accompanied by **renal impairment**. *Chronic pancreatitis* - **Chronic pancreatitis** is a disorder of the pancreas and does not directly impact the **excretion or metabolism** of **digoxin**. - It would not be expected to cause **digoxin accumulation** to toxic levels.
Question 8: 2 year old child with length 85cm and weight of 11kg was found to have serum urea of 49mg/dl, serum creatinine 2mg/dl What is the estimated GFR of this child, as per Schwartz formula?
- A. 48
- B. 9
- C. 19 (Correct Answer)
- D. 90
Explanation: ***19*** - The **Schwartz formula** for estimating GFR in children is: **GFR = k × (length in cm / serum creatinine in mg/dL)**. - For a 2-year-old child, the constant **k is typically 0.45**. Therefore, GFR = 0.45 × (85 cm / 2 mg/dL) = 0.45 × 42.5 = 19.125, which rounds to **19 mL/min/1.73m²**. - This GFR value indicates **moderate to severe chronic kidney disease** in a child. *48* - This value is likely obtained if an incorrect **k constant** was used (such as k = 0.55 for older children) or if there was a calculation error. - A GFR of 48 mL/min/1.73m² would indicate **moderate chronic kidney disease (Stage 3)**, but the calculation using the appropriate k value does not support this. *9* - This value would result from using an incorrect k value (possibly dividing 0.45 by 2) or making an **arithmetic error** in the calculation. - A GFR of 9 mL/min/1.73m² would suggest **severe kidney failure (Stage 5 CKD)**, which is inconsistent with the provided parameters when calculated correctly. *90* - A GFR of 90 mL/min/1.73m² or higher generally indicates **normal kidney function**. - This value is significantly higher than what would be calculated using the Schwartz formula with the given creatinine level of 2 mg/dL, which indicates significant kidney impairment in a child.
Question 9: Which of the following is excreted in saliva?
- A. Lithium (Correct Answer)
- B. Chloramphenicol
- C. Ampicillin
- D. Tetracycline
Explanation: ***Lithium*** - **Lithium** is actively excreted in saliva, making salivary lithium levels a potential, though not routinely used, indicator of serum levels. - The salivary glands can concentrate lithium, leading to concentrations in saliva that are typically **2 to 3 times higher** than in plasma (saliva/plasma ratio of approximately 2-3:1). - This property makes saliva a useful non-invasive medium for therapeutic drug monitoring of lithium. *Chloramphenicol* - **Chloramphenicol** is primarily metabolized in the liver by glucuronidation and excreted in the urine. - While small amounts may be found in various body fluids, it is not a significant component of salivary excretion. *Ampicillin* - **Ampicillin**, a penicillin antibiotic, is mainly eliminated unchanged via renal excretion. - Salivary excretion is not a primary route of elimination for ampicillin. *Tetracycline* - **Tetracycline** antibiotics are primarily excreted unchanged by the kidneys and, to a lesser extent, in bile. - While some drugs can be detected in saliva, tetracycline is not notably excreted through this route in clinically significant amounts.
Question 10: Brand A of liposomal amphotericin B is of innovator company and brand B is of a generic company. AUC of Brand A is 124 mg.h/L and AUC of brand B is 115 mg.h/L. Which of the following statements is correct?
- A. Brand A is bioequivalent to brand B (Correct Answer)
- B. Brand A is not bioequivalent to brand B
- C. Brand A has higher volume of distribution than brand B
- D. Brand B has higher volume of distribution than brand A
Explanation: ***Brand A is bioequivalent to brand B*** - **Bioequivalence** is generally established if the **90% confidence interval** for the ratio of the **AUC** (and Cmax) of the test product (Brand B) to the reference product (Brand A) falls within **80-125%**. - Here, the ratio of AUC (Brand B / Brand A) is 115/124 ≈ 0.927 or 92.7%. This value falls well within the accepted range of 80-125%, indicating bioequivalence. *Brand A is not bioequivalent to brand B* - This statement is incorrect because the AUC ratio (115/124 ≈ 0.927) is within the **standard bioequivalence range of 80-125%**, indicating that the two brands are indeed bioequivalent. - While there are differences in Cmax and Tmax for the two brands as shown in the graph, the provided AUC values suggest bioequivalence for the overall drug exposure. *Brand A has higher volume of distribution than brand B* - The provided **AUC values** (Area Under the Curve) primarily reflect the **extent of drug exposure** and are not directly indicative of the **volume of distribution (Vd)**. - Vd is a pharmacokinetic parameter that relates the total amount of drug in the body to the concentration of the drug in plasma, and it cannot be directly inferred from AUC values alone without additional information like dose and clearance. *Brand B has higher volume of distribution than brand A* - Similar to the previous option, AUC values alone are insufficient to determine the relative **volume of distribution** between the two brands. - Changes in Vd would affect the peak concentration (Cmax) and the elimination half-life, but a definitive conclusion requires more comprehensive pharmacokinetic analysis.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free